Suppr超能文献

Clareon单焦点人工晶状体的有效性和安全性:一项大样本单臂12个月临床研究的结果

Effectiveness and Safety of the Clareon Monofocal Intraocular Lens: Outcomes from a 12-Month Single-Arm Clinical Study in a Large Sample.

作者信息

Lehmann Robert, Maxwell Andrew, Lubeck David M, Fong Raymond, Walters Thomas R, Fakadej Anna

机构信息

Lehmann Eye Center, Nacogdoches, TX, USA.

California Eye Institute, Fresno, CA, USA.

出版信息

Clin Ophthalmol. 2021 Apr 20;15:1647-1657. doi: 10.2147/OPTH.S295008. eCollection 2021.

Abstract

PURPOSE

This study assessed effectiveness and safety of the novel Clareon intraocular lens (IOL; model SY60CL; Alcon Vision LLC).

PATIENTS AND METHODS

This was a prospective, single-arm, unmasked clinical trial at 16 investigative clinical sites in the United States. Included were adults ≥22 years who required cataract extraction by phacoemulsification. Following phacoemulsification, 350 subjects received SY60CL IOL unilaterally; 342 completed the study. Monocular best corrected distance visual acuity (CDVA) and uncorrected distance visual acuity (UDVA) were evaluated. The primary effectiveness endpoint was the percentage of subjects with CDVA ≤0.3 logMAR at month 12. Safety was assessed by monitoring adverse events (AEs). Visual acuity and safety outcomes were compared with historical safety and performance endpoint (SPE) rates.

RESULTS

At 12 months post-implantation, 99.7% of subjects receiving the SY60CL IOL achieved monocular CDVA ≤0.3 logMAR (primary effectiveness endpoint; 1-sided 95% upper confidence limit >SPE rate); 99.7% and 86.8% of subjects achieved monocular CDVA of ≤0.34 (20/40 Snellen or better) and ≤0.04 logMAR (20/20 Snellen or better), respectively. At 12 months, >95% of subjects achieved mean monocular UDVA ≤0.3 logMAR; 97.1% and 57.6% of subjects achieved monocular CDVA of ≤0.34 and ≤0.04 logMAR, respectively. Mean monocular CDVA and UDVA were -0.05 and 0.04 logMAR, respectively. AEs were within SPE limits. The most common nonserious ocular AE was posterior capsule opacification (5.4%). Serious AEs were <1%, and no serious ocular AEs were assessed as related to the device. There were no observations for IOL glistenings at 12 months.

CONCLUSION

Results of this study supported effectiveness and safety of the SY60CL IOL. Visual acuity outcomes with the SY60CL IOL exceeded the SPE rates for monocular CDVA and AEs were within the limit of historic SPE rates. (Model number SY60WF is the Clareon lens approved by the FDA.).

摘要

目的

本研究评估了新型Clareon人工晶状体(IOL;型号SY60CL;爱尔康视觉有限责任公司)的有效性和安全性。

患者与方法

这是一项在美国16个研究临床站点进行的前瞻性、单臂、非盲临床试验。纳入的患者为年龄≥22岁且需要通过超声乳化白内障吸除术治疗白内障的成年人。超声乳化白内障吸除术后,350名受试者单侧植入SY60CL人工晶状体;342名完成了研究。评估了单眼最佳矫正远视力(CDVA)和未矫正远视力(UDVA)。主要有效性终点是术后12个月时CDVA≤0.3 logMAR的受试者百分比。通过监测不良事件(AE)评估安全性。将视力和安全性结果与历史安全性和性能终点(SPE)率进行比较。

结果

植入后12个月,接受SY60CL人工晶状体的受试者中99.7%达到单眼CDVA≤0.3 logMAR(主要有效性终点;单侧95%置信上限>SPE率);99.7%和86.8%的受试者单眼CDVA分别≤0.34(20/40 Snellen或更好)和≤0.04 logMAR(20/20 Snellen或更好)。在12个月时,>95%的受试者单眼平均UDVA≤0.3 logMAR;97.1%和57.6%的受试者单眼CDVA分别≤0.34和≤0.04 logMAR。单眼平均CDVA和UDVA分别为-0.05和0.04 logMAR。不良事件在SPE限度内。最常见的非严重眼部不良事件是后囊膜混浊(5.4%)。严重不良事件<1%,且未评估到任何与该器械相关的严重眼部不良事件。在12个月时未观察到人工晶状体闪烁现象。

结论

本研究结果支持SY60CL人工晶状体的有效性和安全性。SY60CL人工晶状体的视力结果超过了单眼CDVA的SPE率,且不良事件在历史SPE率限度内。(型号SY60WF是美国食品药品监督管理局批准的Clareon人工晶状体。)

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b2e1/8068507/b2c308eb914d/OPTH-15-1647-g0001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验